Atopic Dermatitis Pipeline Outlook 2025: Insights Into Therapies, Research, and Market Potential

DelveInsight's, "Atopic Dermatitis Pipeline Insight, 2025" report provides comprehensive insights about 100+ companies and 120+ pipeline drugs in Atopic Dermatitis pipeline landscape. It covers the Atopic Dermatitis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Atopic Dermatitis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Download our comprehensive report now to explore clinical-stage developments and strategic collaborations transforming the industry! @ Atopic Dermatitis Pipeline Outlook Report- https://www.delveinsight.com/sample-request/atopic-dermatitis-ad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Atopic Dermatitis Pipeline Report
• In August 2025, Alphyn Biologics announced a study aiming to enroll 72 participants across 10 sites in Australia. There are 2 cohorts: Cohort 1: Mild to moderate atopic dermatitis Cohort 2: Mild to moderate atopic dermatitis - with secondary skin infection. Once assigned to a cohort participants will be randomised into 1 of 2 Groups: Arm A: Zabalafin hydrogel or Arm B: vehicle (placebo). Randomisation will be 2:1 ratio. There is up to 2 weeks for screening and study treatment period of 16 weeks.
• In August 2025, Incyte Corporation announced a study is to assess the efficacy and safety of ruxolitinib cream in children and adolescents (6 to
• In August 2025, Inmagene LLC conducted a study to assess the efficacy and safety profile of various dose regimens of IMG-007 in adult participants with moderate-to-severe active atopic dermatitis (AD) up to 52 weeks.
• DelveInsight's Atopic Dermatitis pipeline report depicts a robust space with 100+ active players working to develop 120-+ pipeline therapies for Atopic Dermatitis treatment.
• The leading Atopic Dermatitis Companies such as Vanda Pharmaceuticals, TechnoDerma Medicines, Asana BioSciences, Artax Biopharma, Corvus Pharmaceuticals, Yuhan, BioVersys, Rubedo Life Sciences, Innocare Pharma, Apogee Therapeutics, Celldex Therapeutics, Aclaris Therapeutics, Astria Therapeutics and others.
• Promising Atopic Dermatitis Pipeline Therapies such as Baricitinib, Dupilumab, Lebrikizumab, si-544, Lebrikizumab, MEDI9929, Dupilumab, Midazolam, Omeprazole, Emollient, and others.

Learn how leading Atopic Dermatitis Companies are positioning themselves for success in the evolving pharmaceutical market-access the full report today!" @ Atopic Dermatitis Clinical Trials Assessment- https://www.delveinsight.com/sample-request/atopic-dermatitis-ad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Atopic Dermatitis Emerging Drugs
• ICP-332: Innocare Pharma
ICP-332 is a potent and selective TYK2 inhibitor that is being developed for the treatment of various T-cell related autoimmune disorders, including atopic dermatitis (AD), vitiligo, inflammatory bowel disease, etc., with broad market prospects. As a non-receptor tyrosine kinase, TYK2 is a member of the JAK kinase family, which is an important kinase on the JAK-STAT signaling pathway and plays an important role in the pathogenesis of inflammatory diseases. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Atopic Dermatitis.

• APG777: Apogee Therapeutics
APG777 is a novel, subcutaneous half-life extended monoclonal antibody targeting IL-13 for the potential treatment of AD. In head-to-head preclinical studies, APG777 showed equivalent or better potency to lebrikizumab in the inhibition of IL-13 signaling. APG777 Phase 1 trial data out to 12 months demonstrated a half-life of 77 days, a consistent safety and favorable PD profile showing near complete inhibition of pSTAT6 for up to 12 months after a single administration and sustained TARC inhibition. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Atopic Dermatitis.

• Barzolvolimab: Celldex Therapeutics
Barzolvolimab is a humanized monoclonal antibody that binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity. KIT is expressed in a variety of cells, including mast cells, which mediate inflammatory responses such as hypersensitivity and allergic reactions. KIT signaling controls the differentiation, tissue recruitment, survival and activity of mast cells. In certain inflammatory diseases, such as chronic urticaria, mast cell activation plays a central role in the onset and progression of the disease. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Atopic Dermatitis.

• ATI-2138: Aclaris Therapeutics
ATI-2138 is an investigational oral covalent inhibitor of ITK, and JAK3 for the potential treatment of T cell-mediated autoimmune diseases. The ITK/JAK3 compound interrupts T cell signaling through the combined inhibition of ITK/JAK3 pathways in lymphocytes. Aclaris is developing ATI-2138 as a potential treatment for T cell-mediated autoimmune diseases. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Atopic Dermatitis.

• STAR-0310: Astria Therapeutics
STAR-0310 is a monoclonal antibody designed as an OX40 antagonist, currently in preclinical development by Astria Therapeutics for the treatment of atopic dermatitis (AD) and potentially other immunologic conditions. Its mechanism of action involves inhibiting the OX40 receptor, which plays a critical role in T cell activation and survival, thereby modulating immune responses associated with AD. STAR-0310 is characterized by its high affinity and potency, coupled with a significantly reduced antibody-dependent cellular cytotoxicity (ADCC), which may lead to a more favorable safety profile and a broader therapeutic window compared to existing therapies. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Atopic Dermatitis.

The Atopic Dermatitis Pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Atopic Dermatitis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Atopic Dermatitis Treatment.
• Atopic Dermatitis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Atopic Dermatitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Atopic Dermatitis market.

From early-stage research to late-phase Atopic Dermatitis Clinical Trials, our analysis covers key companies, innovative treatment approaches, and the next wave of Emerging Drugs. Don't miss this opportunity to stay informed-download now! @ Atopic Dermatitis Treatment Drugs- https://www.delveinsight.com/sample-request/atopic-dermatitis-ad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Atopic Dermatitis Companies
Vanda Pharmaceuticals, TechnoDerma Medicines, Asana BioSciences, Artax Biopharma, Corvus Pharmaceuticals, Yuhan, BioVersys, Rubedo Life Sciences, Innocare Pharma, Apogee Therapeutics, Celldex Therapeutics, Aclaris Therapeutics, Astria Therapeutics and others.

Atopic Dermatitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Atopic Dermatitis Products have been categorized under various Molecule types such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Stay updated with the latest Atopic Dermatitis Pipeline Insights-download our report for a deep dive into the next generation of therapeutics! @ Atopic Dermatitis Market Drivers and Barriers, and Future Perspectives- https://www.delveinsight.com/sample-request/atopic-dermatitis-ad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Atopic Dermatitis Pipeline Report
• Coverage- Global
• Atopic Dermatitis Companies- Vanda Pharmaceuticals, TechnoDerma Medicines, Asana BioSciences, Artax Biopharma, Corvus Pharmaceuticals, Yuhan, BioVersys, Rubedo Life Sciences, Innocare Pharma, Apogee Therapeutics, Celldex Therapeutics, Aclaris Therapeutics, Astria Therapeutics and others.
• Atopic Dermatitis Pipeline Therapies- Baricitinib, Dupilumab, Lebrikizumab, si-544, Lebrikizumab, MEDI9929, Dupilumab, Midazolam, Omeprazole, Emollient, and others.
• Atopic Dermatitis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Atopic Dermatitis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Find answers in our latest Atopic Dermatitis Pipeline Insights report, featuring in-depth coverage of Clinical Trials, regulatory trends, and upcoming breakthroughs. Download now to stay at the forefront of pharmaceutical innovation!" @ Atopic Dermatitis Emerging Drugs and Companies- https://www.delveinsight.com/sample-request/atopic-dermatitis-ad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.